■在全球范围内治疗纤维肌痛(FM)症状仍然是一项复杂的工作。本研究致力于评估全身光生物调节(PBM)与安慰剂PBM相比对疼痛的影响,功能,和患有纤维肌痛的个体的心理症状。
■这项研究的主要目的是对全身光生物调节(PBM)和安慰剂PBM对疼痛的影响进行比较分析,功能,和患有纤维肌痛(FM)的患者的心理症状。
■从私人护理实践中招募了总共42名受试者参与这种三盲,安慰剂对照,随机临床试验。参与者接受了12次治疗,并以不同的时间间隔进行评估,包括基线(T0),12期治疗中途(T1),在12届会议(T2)结束时,并在2周(T3)进行随访,3个月(T4),6个月(T5)。
■统计分析显示T2、T3和T5时疼痛显著减轻。此外,在T1,T2,T3,T4和T5时段后,生活质量显著改善.休闲活动在T2,T3,T4和T5时也显示出统计学上的显着改善。此外,在T2,T3,T4和T5治疗后立即显示出两组之间的显着差异。自我效能感,当组间比较时,在T3,T4和T5(治疗后两周)显示出显着差异。最后,疼痛灾难化仅在T5时表现出显着差异。
■这项研究的结果表明,全身PBM治疗4周可以显着减轻疼痛并改善患有FM的个体的生活质量。此外,运动恐惧症和自我效能感在短期和长期评估中都得到了改善,而疼痛灾难在6个月的随访中显示出改善。因此,全身PBM成为FM患者的一种有前途的多因素治疗选择,尽管需要进一步的研究来验证和加强这些结果。临床试验注册:Clinicaltrials.gov,NCT0424897。
UNASSIGNED: The management of fibromyalgia (FM) symptoms on a global scale remains a complex endeavor. This
study endeavors to assess the impact of whole-body photobiomodulation (PBM) compared to placebo PBM on pain, functionality, and psychological symptoms in individuals afflicted with fibromyalgia.
UNASSIGNED: The primary objectives of this research were to conduct a comparative analysis of the effects of whole-body photobiomodulation (PBM) and placebo PBM on pain, functionality, and psychological symptoms in patients suffering from fibromyalgia (FM).
UNASSIGNED: A total of 42 subjects were recruited from a private care practice for participation in this triple-blinded, placebo-controlled, randomized clinical
trial. Participants underwent 12 treatment sessions, and assessments were conducted at various intervals, including baseline (T0), midway through the 12-session treatment (T1), at the completion of the 12 sessions (T2), and follow-ups at 2 weeks (T3), 3 months (T4), and 6 months (T5).
UNASSIGNED: Statistical analysis revealed significant reductions in pain at T2, T3, and T5. Additionally, quality of life exhibited marked improvements after sessions at T1, T2, T3, T4, and T5. Leisure activity also demonstrated statistically significant improvements at T2, T3, T4, and T5. Furthermore, kinesiophobia showed significant differences between groups immediately after treatment at T2, T3, T4, and T5. Self-efficacy, when compared between groups, demonstrated significant differences at T3, T4, and T5 (two weeks after treatment). Lastly, pain catastrophizing exhibited significant differences only at T5.
UNASSIGNED: The findings of this
study indicate that whole-body PBM treatment for 4 weeks resulted in significant pain reduction and improved quality of life in individuals suffering from FM. Furthermore, kinesiophobia and self-efficacy demonstrated improvements in both short-term and long-term assessments, while pain catastrophizing showed improvement at the 6-month follow-up. Consequently, whole-body PBM emerges as a promising multifactorial treatment option for FM patients, though further studies are required to validate and strengthen these results.Clinical
Trial Registration:Clinicaltrials.gov, NCT0424897.